Chemours (CC)
(Delayed Data from NYSE)
$19.57 USD
+0.34 (1.77%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $19.56 -0.01 (-0.05%) 7:58 PM ET
5-Strong Sell of 5 5
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.57 USD
+0.34 (1.77%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $19.56 -0.01 (-0.05%) 7:58 PM ET
5-Strong Sell of 5 5
D Value F Growth A Momentum F VGM
Zacks News
Eastman Chemical (EMN) Gains on Cost Cuts and Innovation
by Zacks Equity Research
Eastman Chemical (EMN) benefits from cost-management actions and innovation amid challenges from soft demand and consumer de-stocking in certain markets.
LyondellBasell's (LYB) Petrothene T3XL7420 to Optimize Production
by Zacks Equity Research
Petrothene T3XL7420 by LyondellBasell (LYB) passes extensive testing and certification procedures to ensure its quality and dependability.
Chemours (CC), DuPont & Corteva Back U.S. Water System Deal
by Zacks Equity Research
Chemours (CC), DuPont & Corteva do not intend to exercise the opt-out option and extend support to PFAS Deal with the U.S. Water System.
Air Products and Chemicals (APD) Up 0.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Air Products and Chemicals (APD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemours (CC) Sets Up International F-gas Lifecycle Program
by Zacks Equity Research
This program by Chemours (CC) will incorporate worldwide monitoring to stimulate further adoption, partnerships and reclamation.
Chemours (CC) Boosts Low GWP HFC-152a Production by 20%
by Zacks Equity Research
Chemours (CC) is increasing HFC-152a production by 20% at its Texas facility to meet the growing demand for eco-friendly propellants and foam-blowing agents.
Chemours (CC) Q3 Earning Miss, Titanium Technologies Hurt Sales
by Zacks Equity Research
Chemours (CC) lags estimates in Q3 amid lower volumes and soft demand.
These 2 Basic Materials Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Compared to Estimates, Chemours (CC) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Chemours (CC) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Chemours (CC) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of -16.88% and 3.63%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights LyondellBasell, Chemours, Axalta Coating Systems and Ashland
by Zacks Equity Research
LyondellBasell, Chemours, Axalta Coating Systems and Ashland are included in this Analyst Blog.
4 Chemical Stocks Set to Pull Off a Beat This Earnings Season
by Anindya Barman
While softer demand in certain end markets is likely to be a drag, LyondellBasell (LYB), Chemours (CC), Axalta Coating Systems (AXTA) and Ashland (ASH) are likely to have benefited from cost and pricing actions.
Why Chemours (CC) Could Beat Earnings Estimates Again
by Zacks Equity Research
Chemours (CC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Earnings Preview: FMC (FMC) Q3 Earnings Expected to Decline
by Zacks Equity Research
FMC (FMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Chemours (CC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How to Find Strong Basic Materials Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Are Options Traders Betting on a Big Move in Chemours (CC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Chemours (CC) stock based on the movements in the options market lately.
Here's Why You Should Hold Onto Chemours (CC) Stock For Now
by Zacks Equity Research
Chemours (CC) gains on strong execution, continued Opteon adoption and its efforts to reduce costs amid headwinds from demand weakness.
Chemours (CC) Benefits From Opteon Adoption Amid Demand Woes
by Zacks Equity Research
Although Chemours (CC) is being challenged by softer demand in certain businesses, it gains on continued Opteon adoption, strong execution and its cost-reduction and pricing actions.
Here's Why You Should Retain Chemours (CC) in Your Portfolio
by Zacks Equity Research
While Chemours (CC) is exposed to headwinds from demand softness in certain areas, it gains on continued Opteon adoption, strong execution and its cost-reduction and pricing actions.
Chemours (CC) Announces Development of New Specialty Fluid
by Zacks Equity Research
Chemours' (CC) introduction of Opteon 2P50 is a critical step in positioning the company to meet a growing challenge brought on by a new era of data transmission.
Cabot (CBT) Joins US Energy Department's Better Plants Program
by Zacks Equity Research
Cabot (CBT) believes that this engagement with the DOE will help the company boost its energy efficiency performance.
Chemours (CC) Q2 Earnings Beat, Titanium Technologies Hurt Sales
by Zacks Equity Research
Chemours' (CC) Titanium Technologies sales were hurt by lower volumes due to weaker demand in all regions in Q2.
Methanex (MEOH) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Methanex (MEOH) delivered earnings and revenue surprises of 9.09% and 4.26%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Huntsman (HUN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Huntsman (HUN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.